The LRRK2-selective type-II inhibitors RN277 and RN341 represent a new set of tool compounds, which will open new avenues for therapeutic development for PD and that harbor significant research potential for uncovering the broader impact of using conformation-specific LRRK2 inhibitors in vivo and in cells. Here, LRRK2 is linked to Parkinson disease.